• Free Global Shipping On Purchases Of 3 Months Or More

Long Awaited Results Are Here
Clinical Study of VigRX Plus​® With Real Individuals is Now Complete

  • 61% improvement in reported sexual drive and desire
  • 71% rise in sexual satisfaction
  • 58% enhancement of hardness
  • 63% increase of staying power
  • 22% rise in the number of orgasms achieved

*Individual results may vary

VigRX Plus® has been clinically tested and proven to be effective by the Vedic Lifesciences Pvt LTD using the Randomized Clinical Trial (RCT) method.

In the RCT, participants were selected at random to receive either a placebo or VigRX Plus®. Neither the participants nor the people administrating and evaluating treatment were aware of which pills were received by any given individual.
The results were overwhelmingly positive, and you can take a look at the findings down below.
The scientifically proven results speak for themselves, but if you want to hear from our clients, you can head over to our review page where you will find real-life testimonials stating the benefits of the product.
You are also invited to read the official Randomized Clinical Trial Report provided by Vedic Lifesciences Pvt LTD for an in-depth exploration of the results.

For the sake of convenience, you can skip the 56-page report and continue to read our summary of the most noteworthy findings below
The triple-blind clinical trial was conducted by Vedic Lifesciences Pvt. Ltd, a leading company in the assessment of supplements.

The organization is committed to providing top quality verifiable data and was among the first to adopt Good Clinical Practices (GCP) – the highest standard of quality control used in the study of human systems.

Vedic Lifesciences Pvt. Ltd is currently one of the top companies for their compliance with the FTC and FDA standards.
VigRX Plus
The Randomized Clinical Trial was conducted over a period of 84 days, and assessments were made on day 28, day 56, and day 84.

Protocols of the RCT were officially approved by the Independent Institutional Ethics Committee (IEC) before testing commenced.

Findings were evaluated using the International Index of Erectile Function (IIEF), a system of assessment with international acclaim and a proven track record.
The IIEF measures:
  • Firmness and frequency of erections
  • Frequency of partner penetration
  • Ability to maintain an erection throughout intercourse, until completion
Satisfaction levels of each partner were assessed with the globally recognized EDITS questionnaire and found to have improved considerably.
The study was conducted on 75 monogamous, heterosexual men between the ages of 25 and 50. Each participant was required to take the advised dosage of VigRX Plus®, which consists of 2 capsules taken twice a day with food for a duration of 12 weeks.

The participants were recruited from a number of volunteers, and selected for their high levels of health (to ensure a controlled assessment of potential side effects).

For this reason, none of the participants had a history of severe mental health issues, alcoholism, heart conditions, liver conditions, STDs, kidney conditions, spinal injuries, diabetes, or deformed reproductive organs.
The participants were tested prior to the clinical trial to determine that their erection issues were not caused by low testosterone levels.

None of the participants were using any form of medication known to result in sexual dysfunction at the time of the trial. It was also ensured that no participant had a pregnant sexual partner.

Now that we’ve covered the basics of the manner in which the tests were conducted, let’s take a more in-depth look at the proven results of the trial:

61% Improvement in Reported Sexual Drive and Desire

One of the top reasons that VigRX Plus® was assessed to be preferable to prescription medication was due to its abilities to enhance sex drive. Most known prescription medication simply offers the benefit of a firm erection – making for a pretty one-sided experience.
VigRX Plus® doubles the pleasure factor by increasing sexual desire once taken. This particular feature is essential to an enjoyable sexual encounter and is highly sought after by those suffering from an erectile disorder. The entire point of sex is inextricably linked to desire and arousal, and our product offers that as part of the package.

71 % Rise in sexual satisfaction

The participants of the VigRX Plus® trial have testified to experiencing a 71.43% increase in sexual pleasure. This was shown to be six times more satisfactory than those who landed up with the placebo. After throwing in that statistic, it may not be necessary to continue, but it just gets better and better.
Not only were the VigRX Plus® users more satisfied, but their partners were as well. Remember that this trial was conducted using the triple-blind method meaning that neither the participants nor the evaluators or administrators were aware of whether the dosage contained a placebo or the VigRX Plus®.

58% Enhancement of hardness

Due to the powerful effects of VigRX Plus®, female partners reported a 58.97% increase in the ability of the participant to penetrate them. VigRX Plus® increased the strength and fullness of the erect participants for fast, effective penetration. 

This was accompanied by the testimonies of enhanced satisfaction and extra pleasurable overall experience. The data was collected by means of the EDITS questionnaire, which was specifically developed as a tool for the assessment of erectile dysfunction products.  

63% Increase in Staying Power

After the full 84 days of supplementing with our star product, VigRX Plus®, participants experienced an increased ability to maintain a powerful erection throughout penetration. 

The erection was notably firmer, thicker, and fuller for the duration of intercourse.

22% Rise in the number of orgasms achieved

Over the 84 days of clinical trial, participants taking the VigRX Plus® were noted to achieve a whopping 22.49% increase in the number of orgasms. This number speaks to the success of the product and certainly to the satisfaction of participants and their partners. 

Who doesn’t want more orgasms? We thought as much.

VigRX Plus® Study References

  • Aytac A, McKinlay JB, Krane RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. Br J Urol Int 1999, 84:450–456
  • Smitasirib Y, D’Souzac P, Neal-Kababickd J, Schauss AG: An Initial Evaluation of the Safety, Efficacy and Purity of VigRX, a Herbal Combination Formula, for the Enhancement of Male Sexual Health. The Open Natural Products Journal 2010, 3:10–19.
  • Barnes PM, Powell-Griner E, McFann K, Nahin RL: Complementary and alternative medicine use among adults: United States, 2002. Advance data from vital and health statistics; no 343. Hyattsville, Maryland: National Center for Health Statistics; 2004
  • Gauthaman K, Ganesan AP: The hormonal effects of Tribulus terrestris and its role in the management of male erectile dysfunction–an evaluation using primates, rabbit and rat. Phytomedicine 2008, 15(1–2):44–54
  • Gauthaman K, Ganesan AP, Prasad RN: Sexual effects of puncturevine (Tribulus terrestris) extract (protodioscin): an evaluation using a rat model. J Altern Complement Med 2003, 9(2):257–265.
  • Pytel Y, Vinarov A, Lopatkin N, Sivkov A, Gorilovsky L, Raynaud J: Long-term clinical and biological effects of the liposterolic extract of serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv Ther 2002, 19(6):297–306.
  • Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC: Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998, 159(5):1541–1547.
  • Montorsi P, Ravagnani PM, Galli S, Rotatori F, Briganti A, Salonia A, Dehò F, Montorsi F: Common grounds for erectile dysfunction and coronary artery disease. Curr Opinion Urol 2004, 14:361–365.
  • Heruti R, Shochat T, Tekes-Manova D, Ashkenazi I, Justo D: Prevalence of erectile dysfunction among young adults: results of a large-scale survey. J Sex Med 2004, 1(3):284–291.
  • Montorsi F, Briganti A, Salonia A, Rigatti P, Margonato A, Macchi A, Galli S, Ravagnani PM, Montorsi P: Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003, 44:360–365.
  • Montorsi P, Ravagnani PM, Galli S, Rotatori F, Veglia F, Briganti A, Salonia A, Deho F, Rigatti P, Montorsi F, Fiorentini C: Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J 2006, 27:2632–2639
  • Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, Wang T: for the GSSAB Investigators’ Group: Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005, 17:39–57.
  • Chitaley K, Webb RC, Mills TM: The ups and downs of Rho-kinase and penile erection: upstream regulators and downstream substrates of rhokinase and their potential role in the erectile response. Int J Impot Res 2003, 15:105–109.
  • Rosen R, Riley A, Wagner G, Osterloh I, Kirkpatrick J, Mishra A: The international index of erectile function (IIEF): a multidimensional scalefor assessment of erectile dysfunction. Urology 1997, 49:822–830.
  • Tian L, Xin ZC, Liu WJ, Yang YM, Liu G, Chen L, Fu J, Wang LL: Effects of icariin on the erectile function and expression of nitrogen oxide synthase isoforms in corpus cavernosum of arterigenic erectile dysfunction rat model. Zhonghua Yi Xue Za Zhi 2004, 84(11):954–957.
  • Giannitsas K, Konstantinopoulos A, Patsialas C, Perimenis P: Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction. Patient Preferences and Adherence 2008, 2:149–155
  • Moore TM, Strauss JL, Herman S, Donatucci CF: Erectile Dysfunction in Early, Middle, and Late Adulthood: Symptom Patterns and Psychosocial Correlates. J Sex Marital Ther 2003, 29(5):381–399.
  • Sun P, Cameron A, Seftel A, Shabsigh R, Niederberger C, Guay A: Erectile dysfunction–an observable marker of diabetes mellitus? A large national epidemiological study. J Urol 2006, 176(3):1081–1085
  • Lizza EF, Rosen RC: Definition and classification of erectile dysfunction: Report of the nomenclature committee of the International Society of Impotence Research. Int J Impot Res 1999, 11:141–143.
VigRX Plus
Get Your Supply of VigRX Plus® Today